RVC's Biofund, an RVC OJSC Portfolio Fund, in partnership with IR Russ-Invest made a decision to continue financing the company and to provide the second tranche to Semiotics Company specializing in the design and manufacture of unique microarrays for blood and plasma donation analysis.
On March 21, BioEq, Russia’s first commercial R&D center for early phase studies has been opened in St. Petersburg.
Human Stem Cell Institute – HSCI, OJSC, a Russian biotech company developing and implementing products and services in the field of cellular, genetic, and post-genomic technologies – announced signing an Investment Agreement with RVC Biofund.
The investment committee of RVC Biofund has approved the investment in Andrus Reo, a recently established startup which will conduct phase III clinical trials for an antineoplastic drug in Russia and the CIS.